Orchestra BioMed Holdings, Inc.
Health
Performance
6.3
Risk
Sell
Buy
Curious about the Scores? Learn more.

Orchestra BioMed Holdings, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

17.10.2026
Trouble brewing. Volatility and pressure rising.
14.10.2026
Breaking down. The red game over screen is flashing.
15.09.2026
Losing steam. Not trending your way right now.
OBIO
Orchestra BioMed Holdings, Inc.
5.45
-5.05%
6.3
Sell
Buy
Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Orchestra BioMed Holdings, Inc. do? Business model and key facts

Get the full picture of Orchestra BioMed Holdings, Inc.: what it builds, where it operates, and how it makes money.

Orchestra BioMed Holdings, Inc. Profile

Sector: Healthcare

Industry: Biotechnology

Employees (FY): 86

Orchestra BioMed Holdings, Inc. is an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company has formed strategic collaborations with Medtronic on BackBeat CNT and with Terumo Corporation on Virtue SAB. Its headquarters are located in New Hope, Pennsylvania.

shop
Company facts
David Hochman
CEO
86
Employees worldwide
shop
Performance
64.16%
Last 12 months
-44.61%
Last 5 years
shop
Growth
$33.48M
Revenue year
$-52,701,000
Net income
shop
Valuation
$327.57M
Market Cap
-3.74
Price/Earnings Ratio

Stocks related to Orchestra BioMed Holdings, Inc.

Selected based on industry alignment and relative market positioning.

YDES
YD Bio Limited Ordinary Shares
5.92
-12.17%
8.1
Sell
Buy
YD Bio Limited Ordinary Shares
PRTA
Prothena Corporation plc
8.35
-1.76%
5.4
Sell
Buy
Prothena Corporation plc
CTMX
CytomX Therapeutics, Inc.
2.28
-5.39%
10.0
Sell
Buy
CytomX Therapeutics, Inc.
IRD
Opus Genetics, Inc.
3.84
-5.19%
8.7
Sell
Buy
Opus Genetics, Inc.
ARCT
Arcturus Therapeutics Holdings Inc.
10.34
-8.25%
10.0
Sell
Buy
Arcturus Therapeutics Holdings Inc.

Orchestra BioMed Holdings, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.